- Featured
Adelaide, SA
Recruiting
- Featured
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety and tolerability of HZN-825 in subjects with IPF. Subjects will be screened within 8 weeks prior to the Baseline (Day 1) Visit. Approximately 360 subjects who meet the trial eligibility criteria will be randomly assigned in a 1:1:1 ratio on Day 1 to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks using the following 2 stratification factors: Prior use of approved IPF therapy (i.e., nintedanib or pirfenidone): yes or no; FVC % predicted at Baseline: ≥70% or <70%.
Phase
2Span
123 weeksSponsor
Horizon Therapeutics Ireland DACAdelaide
Recruiting
A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).
Phase
1/2Span
144 weeksSponsor
Eupraxia Pharmaceuticals Inc.Adelaide, South Australia
Recruiting
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants with PMM2-CDG
Phase
2Span
157 weeksSponsor
Glycomine, Inc.Adelaide, South Australia
Recruiting
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Phase
3Span
209 weeksSponsor
Hoffmann-La RocheAdelaide, South Australia
Recruiting
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Phase
3Span
290 weeksSponsor
Merck Sharp & Dohme LLCAdelaide, South Australia
Recruiting
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks.
Phase
3Span
181 weeksSponsor
Bellus Health Inc. - a GSK companyAdelaide, South Australia
Recruiting
Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease
The SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter is an investigational medical device to be used to treat de-novo lesions in patients with symptomatic stable angina, unstable angina, and NSTEMI. In this study, SirPlux Duo™ will be used in subjects undergoing a planned percutaneous coronary intervention. The population to treat will include those with de-novo coronary lesions in vessels with a reference vessel diameter (RVD) of ≥2.0 and ≤4.0 mm and a total lesion length of <36mm with documented symptomatic stable angina, unstable angina, or NSTEMI. The study is a prospective, single-arm, multi-center, safety and feasibility first-in-human study designed to generate descriptive data about the use of SirPlux Duo™.
Phase
N/ASpan
218 weeksSponsor
Advanced NanoTherapiesAdelaide, South Australia
Recruiting
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Phase
N/ASpan
312 weeksSponsor
Western Sydney Local Health DistrictAdelaide, South Australia
Recruiting
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
YH32367, a novel HER2/4-1BB bispecific antibody (BsAb), simultaneously targets HER2 and h4-1BB and binds to both targets. YH32367 exhibits a strong 4-1BB signal activation as well as blocking of HER2 signaling in HER2-expressing tumor cells. YH32367 stimulates IFN-γ secretion from T cells and thereby induces tumor cells lysis. This is a Phase 1/2, open-label, multicenter, first-in-human study of YH32367. This 2-part study will include both a Dose Escalation part, to identify the Maximum Tolerated Dose (MTD) and/or two dose levels for RP2D selection, and a Dose Expansion part, to determine RP2D and to confirm the safety, tolerability and efficacy of YH32367 at the RP2D.
Phase
1/2Span
223 weeksSponsor
Yuhan CorporationAdelaide
Recruiting